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Nørregaard R, Jensen BL, Topcu SO, Diget M, Schweer H,
Knepper MA, Nielsen S, Frøkiær J. COX-2 activity transiently
contributes to increased water and NaCl excretion in the polyuric
phase after release of ureteral obstruction. Am J Physiol Renal Physiol
292: F1322–F1333, 2007. First published January 16, 2007;
doi:10.1152/ajprenal.00394.2006.—Release of bilateral ureteral ob-
struction (BUO) is associated with reduced expression of renal aqua-
porins (AQPs), polyuria, and impairment of urine-concentrating ca-
pacity. Recently, we demonstrated that 24 h of BUO is associated with
increased cyclooxygenase (COX)-2 expression in the inner medulla
(IM) and that selective COX-2 inhibition prevents downregulation of
AQP2. In the present study, we tested the hypothesis that COX-2
activity increases in the postobstructive phase and that this increase in
COX-2 activity contributes to polyuria and impaired urine-concen-
trating capacity. We examined the effect of the selective COX-2
inhibitor parecoxib (5 mg kg1 day1 via osmotic minipumps) on
renal functions and protein abundance of AQP2, AQP3, Na-K-2Cl
cotransporter type 2 (NKCC2), and Na-K-ATPase 3 days after release
of BUO. At 3 days after release of BUO, rats exhibited polyuria,
dehydration and urine and IM tissue osmolality were decreased. There
were inverse changes of COX-1 and COX-2 in the IM: COX-2
mRNA, protein, and activity increased, while COX-1 mRNA and
protein decreased. Parecoxib reduced urine output 1 day after release
of BUO, but sodium excretion and glomerular filtration rate were
unchanged. Parecoxib normalized urinary PGE2 and PGI2 excretion
and attenuated downregulation of AQP2 and AQP3, while phosphor-
ylated AQP2 and NKCC2 remained suppressed. Parecoxib did not
improve urine-concentrating capacity in response to 24 h of water
deprivation. We conclude that decreased NKCC2 and collapse of the
IM osmotic gradient, together with suppressed phosphorylated AQP2,
are likely causes for the impaired urine-concentrating capacity and
that COX-2 activity is not likely to mediate these changes in the
chronic postobstructive phase after ureteral obstruction.
cyclooxygenase; ureteral obstruction; PGE2; parecoxib; AQP2;
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IT IS WELL ESTABLISHED that release of complete obstruction of
the urinary tract in humans is associated with extreme polyuria
and impairment of the urine-concentrating capacity (7). Son-
nenberg et al. (35) demonstrated markedly lower water perme-
ability in the medullary collecting ducts of rats subjected to
postobstructive diuresis after release of 24 h of bilateral ure-
teral ligation. Consistent with this finding, we previously
showed that release of bilateral ureteral obstruction (BUO) in
rats is associated with long-term downregulation of the col-
lecting duct water channels aquaporin (AQP)-2 and AQP3
(24). Moreover, as recently demonstrated, selective downregu-
lation of AQP2 in postobstructed kidney may account for the
higher excretion of hypotonic urine, and the local increase in
PGE2 synthesis in postobstructed kidney may be involved in
AQP2 downregulation (27). Concurrently, urine-concentrating
capacity in rats is impaired for 30 days (24). Urine-concen-
trating capacity depends on AVP-mediated dynamic changes in
water permeability of the collecting ducts, as well as on the
medullary interstitial osmotic gradient set up by the thick
ascending limb of Henle’s loop (TAL).
In response to 24 h of BUO, the protein expression of the
Na-K-2Cl type 2 cotransporter (NKCC2), which is crucial for
establishing the single effect of the osmotic gradient, is down-
regulated and the medullary interstitial osmolality is signifi-
cantly lower than in sham-operated rats (33). Previous studies
indicate that the cyclooxygenase (COX)-prostanoid pathway
may contribute to renal function changes after obstruction (2,
28). It has recently been demonstrated that 24 h of BUO
enhances PGE2 production in cortical and medullary tubules of
the rat kidney (37) and that PGE2 is an established inhibitor of
vasopressin-stimulated osmotic water permeability and sodium
transport in collecting duct principal cells (18, 32). COX
activity exerts tonic suppression of NKCC2 abundance in the
TAL (10). Enhanced PGE2 production after ureteral obstruc-
tion is mediated predominantly by COX-2. Consistent with
this, we and others previously demonstrated that COX-2 ex-
pression is markedly increased in the inner medulla (IM) in
response to unilateral ureteral obstruction (UUO) (3) and BUO
(2, 28). Importantly, selective COX-2 inhibition attenuates
downregulation of AQP2 and NKCC2 in response to BUO
(28). Moreover, it was recently demonstrated that urine output
in the first hours after release of obstruction is restored toward
normal in rats treated with the COX-2 inhibitor NS-398 (2).
These data led us to hypothesize a causal relation between
increased COX-2 activity and chronic postobstructive polyuria
and reduced urine-concentrating ability subsequent to BUO.
In the present study, our aims were therefore to examine
1) whether the postobstructive-induced (3 days after release of
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BUO) natriuresis and diuresis, as well as reduced urine-con-
centrating capacity, in rats are associated with changes in the
localization, abundance, and activity of COXs in kidney, 2)
whether selective COX-2 inhibition after release of BUO
abrogates or diminishes natriuresis and diuresis and restores
urine-concentrating capacity, and 3) whether selective COX-2
inhibition attenuates downregulation of crucial transport pro-
teins involved in the urine-concentrating capacity, i.e., Na-K-
ATPase, NKCC2, AQP2, phosphorylated AQP2 (pAQP2), and
AQP3.
METHODS
Experimental animals. All procedures conformed with the Danish
national guidelines for the care and handling of animals and the
published guidelines from the National Institutes of Health. The
animal protocols were approved by the board of the Institute of
Clinical Medicine of the University of Aarhus according to the
licenses for use of experimental animals issued by the Danish Min-
istry of Justice. Male Munich-Wistar rats (250 g initial body wt;
Møllegaard Breeding Centre, Eiby, Denmark) had free access to a
standard rodent diet (Altromin, Lage, Germany) and tap water. During
the experiments, the rats were kept in individual metabolic cages, with
a 12:12-h light-dark cycle, at 21  2°C and 55  2% humidity. The
rats were allowed to acclimatize to the cages 3–4 days before surgery.
Anesthesia was induced with isoflurane (Abbott Scandinavia), and
during the operation, the rats were placed on a heating pad to maintain
rectal temperature at 37–38°C. Through a midline abdominal incision,
both ureters were exposed, and a 5-mm-long piece of bisected poly-
ethylene (PE-50) tubing was placed around the midportion of each
ureter. The tubing was tightened with a 5-0 silk ligature to occlude the
ureter. After 24 h, the obstructed ureters were decompressed by
removal of the ligature and tubing.
The rats were allocated to protocols 1–3 (see below). Age- and
time-matched, sham-operated controls (SHAM) were prepared and
observed in parallel with each BUO group as follows (Fig. 1).
Protocol 1. 1) BUO was induced for 24 h followed by 3 days of
release (n  8). Left kidneys were prepared for semiquantitative
immunoblotting and right kidneys for quantitative PCR (QPCR, n  5);
kidneys were also prepared for immunocytochemistry (n  3). 2)
SHAM rats were prepared in parallel (n  8). Left kidneys were
prepared for semiquantitative immunoblotting and right kidneys for
QPCR (n  5); kidneys were also prepared for immunocytochemistry
(n  3).
Protocol 2. 1) BUO was induced for 24 h followed by 3 days of
release. In group 1, osmotic minipumps (Alzet, Scanbur, Denmark)
containing saline were surgically implanted subcutaneously (n  12).
In group 2, osmotic minipumps containing parecoxib (Dynastat,
Pfizer, Ballerup, Denmark) dissolved in saline (40 mg/ml) were
surgically implanted subcutaneously when the obstruction was per-
formed, and parecoxib was administered at 5 mg  kg1  day1
throughout the treatment period (n  12). 2) SHAM rats were
subjected to a similar surgical procedure without ureteral occlusion. In
group 3, osmotic minipumps containing saline were implanted sub-
cutaneously (n  10). In group 4, osmotic minipumps containing
parecoxib dissolved in saline (40 mg/ml) were surgically implanted
subcutaneously, and parecoxib was administered at 5 mg kg1 day1
throughout the control period (n  10). Administration of parecoxib at
5 mg kg1 day1 was based on a previously demonstrated pharma-
cological profile of parecoxib (30). Left kidneys were prepared for
semiquantitative immunoblotting and QPCR and right kidneys for
measurements of IM osmolality in the BUO (n  8) and SHAM (n 
6) rats; kidneys were also prepared for immunocytochemistry (n 4).
Protocol 3. 1) BUO was induced for 24 h followed by 3 days of
release. Urine-concentrating capacity in response to 24 h of water
Fig. 1. Study design. Protocol 1: bilateral
ureteral obstruction (BUO) was created and
released after 24 h, and rats were monitored
for the following 3 days. Sham-operated
control rats matching BUO rats were also
created. Protocol 2: BUO rats were divided
into nontreated (vehicle) and parecoxib-
treated (5 mg  kg1  day1 via osmotic
minipumps) groups. SHAM rats were divided
into nontreated (vehicle) and parecoxib-
treated groups. Protocol 3: BUO was created
and released after 24 h. Rats were monitored
for the following 3 days, and then water
deprived for 24 h. BUO rats were divided into
nontreated (vehicle) and parecoxib-treated
groups. All rats were kept in metabolic cages
throughout the study. Urine was collected
daily, and plasma was collected when rats
were killed (Death).
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deprivation was examined 3–4 days after release of BUO. In group 1,
saline-containing osmotic minipumps were surgically implanted sub-
cutaneously (n  8). In group 2, osmotic minipumps containing
parecoxib dissolved in saline (40 mg/ml) were surgically implanted
subcutaneously when the obstruction was performed, and parecoxib
was administered at 5 mg kg1 day1 throughout the treatment
period (n  8). 2) SHAM rats were operated in parallel. In group 3,
osmotic minipumps containing saline were implanted subcutaneously
(n  6).
Clearance studies. Urine was collected over 24-h period in pro-
tocols 2 and 3, and clearance studies were performed during the last
24 h in each protocol. The rats were reanesthetized with isoflurane at
the end of each protocol. Before each rat was killed, the aortic
bifurcation was localized and dissected free, and a 5- to 7-ml blood
sample was collected for determination of plasma electrolytes and
osmolality. The kidneys were rapidly removed, and the IM was
dissected and frozen in liquid nitrogen. The plasma and urine con-
centrations of creatinine and urea were measured (Vitros 950, Johnson
& Johnson). Finally, osmolality of the plasma and urine was deter-
mined with a vapor pressure osmometer (Osmomat 030, Gonotec,
Berlin, Germany).
Measurement of IM osmolality. Tissue was processed by a modi-
fication of the method described by Schmidt-Nielsen et al. (33).
Briefly, kidneys were removed, and individual IMs were rapidly
excised, snapfrozen in liquid nitrogen and stored at 80°C. During
the analysis, the IMs were placed in preweighed tubes. Samples were
weighed immediately and subsequently dried over a desiccant at 60°C
Fig. 2. Expression of cyclooxygenase (COX)-2 mRNA and protein in the
inner medulla (IM) from SHAM and BUO rats. A: representative quantitative
PCR (QPCR) for COX-2 and TATA box-binding protein (TBP). For QPCR,
100 ng of cDNA were used. Values are means  SE. *P  0.05 BUO vs.
SHAM. B: immunoblot reacted with anti-COX-2 antibody. Note 2 discernible
bands (72 and 74-kDa). A total of 20 g of protein were used for COX-2 assay.
Densitometric analyses of all samples revealed an increase of COX-2 protein
in BUO rats compared with SHAM rats. Values are means  SE. *P  0.05
BUO vs. SHAM. C and D: immunohistochemistry for COX-2 at the base of the
IM of SHAM and BUO rats. COX-2 immunoreactivity was detected in
interstitial cells, and labeling was much stronger in BUO than in SHAM rats.
Fig. 3. COX-1 mRNA and protein expression in the IM of SHAM and BUO
rats. A: representative QPCR for COX-1 and TBP. For QPCR, 100 ng of
cDNA were used. Values are means  SE. *P  0.05 BUO vs. SHAM.
B: immunoblot reacted with anti-COX-1 antibody. Note 71-kDa band. A total
of 20 g protein were used for COX-1 assay. Densitometric analyses of all
samples revealed a decrease of COX-1 protein level in BUO rats compared
with SHAM rats. Values are means  SE. *P  0.05 BUO vs. SHAM. C and
D: immunohistochemistry for COX-1 at the base of the IM of SHAM and BUO
rats. COX-1 immunoreactivity was detected in interstitial cells and collecting
ducts, and labeling was much weaker in BUO than in SHAM rats.
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for 2.5 h (after which weight remained constant). After the samples
were reweighed, 150 l of distilled water were added to each tube.
The tubes were capped, kept at 95°C for 30 min, and, after brief
centrifugation, stored at 4°C for 24 h for diffusion. After centrifuga-
tion for 1 min at 8,000 g, supernatant osmolality was determined with
a vapor pressure osmometer (Osmomat 030, Gonotec).
Measurement of urinary prostanoid excretion before and after
release of obstruction. In an isotope-dilution assay, PGE2 and the
PGI2 metabolite 6-keto-PGF1 were determined in urine by gas
chromatography-tandem mass spectrometry (GC-MS-MS). After ad-
dition of deuterated internal standards, the prostanoids were deriva-
tized to methoximes and extracted with ethyl acetate-hexane. The
samples were further derivatized to the pentafluorobenzyl esters and
purified using TLC. Three zones were scraped from the TLC. The
prostanoid derivatives were converted to the trimethylsilyl ethers, and
the products were quantified using GC-MS-MS.
GC-MS-MS analysis. A GC-MS-MS (model MAT TSQ700, Finni-
gan) equipped with a gas chromatograph (Varian 3400) and an
autosampler (model CTC A200S) was used. Gas chromatography of
prostanoid derivatives was carried out on a DB-1 (20-m, 0.25-mm ID,
0.25-m film thickness) capillary column (Analyt, Mu¨hlheim,
Germany) in the splitless mode. GC-MS-MS parameters were exactly
as described by Schweer et al. (34).
QPCR. For QPCR, 100 ng of cDNA served as a template for
PCR amplification using Brilliant SYBR Green QPCR Master Mix
according to the manufacturer’s instruction (Stratagene). Serial
dilution (1 ng–1 fg/l) of cDNA was used as template for generation
of a standard curve. Nested primers were used to amplify standards
and kidney cDNA samples as follows: GGA ATT CAA CCA CCT
CTA TCA CTG (sense) and GAC ACC GTA GTC CAC CAG CAT
A (antisense) for COX-1 (GenBank accession no. NM_017043, 121
bp), CCT TGA AGA CGG ACT TGC TCA C (sense) and TCT CTC
TGC TCT GGT CAA TGG A (antisense) for COX-2 (GenBank
accession no. U03389, 131 bp), ACC AAG AAC CTC CCT CCT GT
(sense) and TCG GAC ACC AAG GTA CAA CA (antisense) for
NKCC2 (GenBank accession no. NM_019134, 107 bp), and GAC
TCC TGT CTC CCC TAC CC (sense) and CTC AGT GCA GAG
GAG GGA AC (antisense) for TATA box-binding protein (TBP;
GenBank accession no. NM_001004198, 162 bp). Standards and
unknown samples were amplified in duplicate in 96-well plates, and
PCR was performed for 50 cycles, consisting of denaturation for 30 s
at 95°C followed by annealing and polymerization at 60°C for 1 min.
Emitted fluorescence was detected during the annealing/extension
step in each cycle. Specificity was ensured by postrun melting curve
analysis.
Membrane fractionation for immunoblotting. Tissue from the IM
was homogenized in dissecting buffer [0.3 M sucrose, 25 mM imid-
azole, 1 mM EDTA (pH 7.2), and the protease inhibitors 8.5 M
leupeptin (a serine and cysteine protease inhibitor; Sigma-Aldrich)
and 0.4 mM Pefabloc (a serine protease inhibitor; Roche)]. Moreover
dissecting buffer for the IM was added after addition of the phospha-
tase inhibitors sodium orthovanadate (Sigma-Aldrich), NaF (Merck),
and okadaic acid (Calbiochem). The tissue was homogenized for 30 s
at 1,250 rpm (Ultra-Turrax T8 homogenizer, IKA Labortechnik) and
then centrifuged at 4,500 g at 4°C for 15 min. Gel samples were
prepared from the supernantant in Laemmli sample buffer containing
2% SDS. For COX-1 and COX-2, homogenates were homogenized
for 30 s at 1,250 rpm (Ultra-Turrax T8 homogenizer) in dissecting
buffer and then centrifuged at 10,000 g for 10 min. The supernatant
was centrifuged for 60 min at 100,000 g to sediment microsomes, as
described previously (15). The microsomes were resuspended in
dissecting buffer, mixed with an equal volume of 2 SDS sample
buffer, and boiled for 5 min. Total protein concentration of the
homogenate was measured using a Pierce bicinchoninic acid protein
assay kit (Roche).
Electrophoresis and immunoblotting. Samples of membrane frac-
tionation from the IM were run on a 12% polyacrylamide minigel
Fig. 4. Urine output and osmolality in parecoxib-treated and untreated (vehi-
cle) BUO rats compared with SHAM rats in protocol 2. Values are means 
SE (n  6 SHAM and 8 BUO). *P  0.05 BUO vs. SHAM. $ P  0.05 BUO
 parecoxib vs. BUO  vehicle.
Table 1. GFR, urine, and plasma biochemical values: protocol 2
SHAM  Vehicle
(n  6)
SHAM  Parecoxib
(n  6)
BUO  Vehicle
(n  8)
BUO  Parecoxib
(n  8)
GFR, l  min1  kg1 9.50.5 7.80.8 3.40.5* 4.20.8*
TcH2O, l  min1  kg1 17515.5 14617.3 86.15.7* 61.89.9*
Posmol, mosmol/kgH2O 3001.2 3022.3 3135.2* 32713*
Purea, mM 6.40.3 6.10.3 12.63.4* 10.31.9*
Uurea, mM 1,269162 1,172122 46051* 41042*
Values are means  SE; n, number of rats. SHAM, sham-operated control rats; BUO, bilateral ureteral obstruction; GFR, glomerular filtration rate; TcH2O
solute-free water reabsorption; Posmol, plasma osmolality; Purea, plasma urea concentration; Uurea, urine urea concentration. *P  0.05 BUO vs. SHAM.
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(Mini Protean II, Bio-Rad). For each gel, an identical gel was run in
parallel and subjected to Coomassie staining. The Coomassie-stained
gel was used to determine identical loading or to allow for correction
for minor variations in loading.
Samples were run on 9 and 12% polyacrylamide gels (Mini Protean
II, Bio-Rad). Proteins were transferred to a nitrocellulose membrane
(Hybond ECL RPN 3032D, Amersham Pharmacia Biotech). The blots
were blocked with 5% nonfat dry milk in PBS-T (80 mM Na2HPO4,
20 mM NaH2PO4, 100 mM NaCl, and 0.1 Tween 20, adjusted to pH
7.4). After they were washed with PBS-T, the blots were incubated
with primary antibodies overnight at 4°C. Antigen-antibody complex
was visualized with horseradish peroxidase-conjugated secondary
antibodies (diluted 1:3,000; catalog no. P448, Dako, Glostrup,
Denmark) using an enhanced chemiluminiscence system (ECL, Amers-
ham Pharmacia Biotech). For immunolabeling controls, peptide-ab-
sorbed antibody was used.
Primary antibodies. For semiquantitative immunoblotting and im-
munocytochemistry, we used previously characterized monoclonal
and polyclonal antibodies as follows: an affinity-purified rabbit poly-
clonal antibody against COX-1 (catalog no. 160109, Cayman Chem-
ical, Ann Arbor, MI); an affinity-purified rabbit polyclonal antibody
against COX-2 (catalog no. 160126, Cayman Chemical); an immune
serum or an affinity-purified antibody to AQP2 (LL127 serum or
LL127AP), as previously described (6); an affinity-purified rabbit
polyclonal antibody to pAQP2 (AN224-pp-AP), as previously de-
scribed (4); an affinity-purified polyclonal antibody to AQP3
(LL178AP), as previously described (8); a monoclonal antibody
against the 1-subunit of Na-K-ATPase, as previously described (21);
and an affinity-purified polyclonal antibody to the apical Na-K-2Cl
cotransporter of the TAL (LL320AP), as previously described (9).
Immunocytochemistry. The kidneys from BUO and SHAM rats
were fixed by retrograde perfusion via the abdominal aorta with 3%
paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4). Moreover, the
kidneys were immersion fixed for 1 h and washed three times for 10
min each with 0.1 M cacodylate buffer. The kidney blocks were
dehydrated and embedded in paraffin. The paraffin-embedded tissues
were cut into 2-m sections on a rotary microtome (Leica Microsys-
tems, Herlev, Denmark).
For immunoperoxidase labeling, the sections were deparaffinated
and rehydrated. Endogenous peroxidase activity was blocked with 5%
H2O2 in absolute methanol for 10 min at room temperature. For
exposure of antigens, kidney sections were boiled in a target retrieval
solution [1 mmol/l Tris (pH 9.0) with 0.5 mM EGTA] for 10 min.
After the sections were cooled, they were incubated in 50 mM NH4Cl
in PBS for 30 min to prevent nonspecific binding and then blocked in
PBS containing 1% BSA, 0.05% saponin, and 0.2% gelatin. Sections
were incubated with primary antibodies diluted in PBS with 0.1%
BSA and 0.3% Triton X-100 overnight at 4°C. After they were
washed three times for 10 min each with PBS supplemented with
0.1% BSA, 0.05% saponin, and 0.2% gelatin, the sections were
incubated with horseradish peroxidase-conjugated secondary antibody
(catalog no. P448, goat anti-rabbit immunoglobulin, Dako) for 1 h at
room temperature. After the sections were rinsed with PBS wash
buffer, the sites of antibody-antigen reactions were visualized with
0.05% 3,3	-diaminobenzidine tetrachloride (Kem-en Tek, Copenha-
gen, Denmark) dissolved in distilled water with 0.1% H2O2. The
Fig. 5. Effect of parecoxib on urinary excretion of PGE2 and the PGI2
metabolite 6-keto-PGF1. BUO was induced for 24 h followed by 3 days of
release. Parecoxib (5 mg  kg1  day1) or saline was administrated in osmotic
minipumps during obstructed and release periods. PGE2 and 6-keto-PGF1
were measured before obstruction (day 1) and on 1 and 3 days after release.
Values are means  SE (n  6 SHAM and 8 BUO). *P  0.05 BUO vs.
SHAM. $ P  0.05 BUO  parecoxib vs. BUO  vehicle.
Table 2. Changes in renal sodium excretion after release of BUO: protocol 2
SHAM  Vehicle
(n  6)
SHAM  Parecoxib
(n  6)
BUO  Vehicle
(n  8)
BUO  Parecoxib
(n  8)
Na excretion, mol  min1  kg1
Day  1 4.20.2 4.70.4 3.70.1 3.70.2
Day 1 5.80.4 6.10.4 11.11.7* 9.11.1*
Day 3 4.60.4 3.80.4 1.70.4* 1.60.5*
FlNa, mol  min1  kg1 1,32867 1,087118 47860* 584117*
Net Na reabsorption, mol  min1  kg1 1,32366 1,084118 47661* 582116*
Values are means  SE; n, number of rats. FLNa, filtered load of sodium. *P  0.05 BUO vs. SHAM.
Table 3. GFR and urine and plasma biochemical
values: protocol 3
SHAM  Vehicle
(n  6)
BUO  Vehicle
(n  8)
BUO  Parecoxib
(n  8)
GFR, l/min/kg 6.70.5 4.50.6* 3.70.6*
TcH2O, l/min/kg 12810.1 110.58.9 99.219.8
Posmol, mosmol/kgH2O 3141.3 3232.6* 3346.2*
Purea, mM 8.60.5 8.81.1 13.44.4
Uurea, mM 1,904218 946111* 869102*
Values are means  SE; n, number of rats. *P  0.05 BUO vs. SHAM.
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sections were observed under a light microscope (model DMRE,
Leica Microsystem).
Statistics. Values are means SE. Statistical comparisons between
experimental groups were made by a standard unpaired t-test or
one-way ANOVA with Bonferroni’s correction. P  0.05 was con-
sidered significant.
RESULTS
Increased renal IM COX-2 expression after release of 24-h
BUO. The abundance of COX-2 mRNA normalized for TBP
was significantly increased 1.5-fold in the BUO rats compared
with the SHAM rats (Fig. 2A). Semiquantitative immunoblot-
ting showed that BUO followed by 3 days of release signifi-
cantly induced COX-2 (P  0.05; Fig. 2B). Immunohisto-
chemistry revealed localization of COX-2 protein in the med-
ullary interstitial cells and there was a marked increase in
COX-2 labeling of the interstitial cells at the base of the IM in
BUO rats (Fig. 2D) compared with SHAM rats (Fig. 2C).
COX-1 mRNA normalized for TBP decreased signifi-
cantly in the IM of BUO rats compared with SHAM rats
(Fig. 3A). In accordance, the protein expression of COX-1
was reduced in the IM in BUO rats compared with SHAM
rats (P  0.01; Fig. 3B). Consistent with the reduced mRNA
and protein expression, immunohistochemical analysis of
COX-1 protein demonstrated a marked reduction in labeling
of the collecting ducts and the interstitial cells at the base
of the IM in BUO rats compared with SHAM rats (Fig. 3,
C and D).
Effect of COX-2 inhibition on BUO-mediated changes in
glomerular filtration rate, diuresis, and plasma and urine
electrolytes 3 days after BUO release. In protocol 2, the effect
of the selective COX-2 inhibitor parecoxib (5 mg kg1 day1)
on renal function parameters and transport proteins was exam-
ined before and 3 days after release of BUO.
Glomerular filtration rate (GFR) and solute-free water reab-
sorption were significantly reduced in BUO rats compared with
SHAM rats (Table 1). Plasma osmolality and urea were ele-
vated 3 days after release of BUO, while urinary urea concen-
tration was reduced (Table 1). Thus BUO rats were dehydrated
3 days after obstruction was released. Parecoxib did not affect
these parameters in the SHAM or BUO rats (Table 1). Urine
output did not differ between vehicle- and parecoxib-treated
SHAM rats over the 5 study days (Fig. 4A). In marked contrast,
urine output increased fivefold 1 day after release of obstruc-
tion and then slowly recovered in BUO vehicle-treated rats, but
urine output remained significantly higher 3 days after release
of BUO than in control rats (Fig. 4A). Parecoxib significantly
lowered urine output 1 day after release of BUO but had no
significant effect 2 and 3 days after release of obstruction
(Fig. 4A). Sodium excretion displayed a biphasic change: it
increased markedly 1 day after release of obstruction, whereas
3 days after release of BUO it was significantly lower than in
SHAM rats (Table 2). The filtered load of sodium and net
reabsorption of sodium were lower 3 days after release of BUO
(Table 2). Parecoxib did not change sodium excretion after
release of obstruction (Table 2).
There was no significant difference between the untreated and
treated SHAM rats with regard to urine osmolality (Fig. 4B). In
contrast, urine osmolality decreased fivefold 1 day after release
of obstruction and then recovered significantly 2 and 3 days
after release (Fig. 4B). Urine osmolality was significantly
lower 3 days after release of BUO than in SHAM rats, and
inhibition of COX-2 did not alter these changes in urine
osmolality after release of obstruction (Fig. 4B). Renal IM
tissue interstitial osmolality was determined in protocol 2 (3
days after release of the obstruction). Interstitial osmolality
Fig. 6. Urine output and osmolality in parecoxib-treated and untreated BUO
rats compared with matched SHAM rats in protocol 3. Values are means SE
(n  6 SHAM and 8 BUO). WD, water deprivation. *P  0.05 BUO vs.
SHAM. $ P  0.05 BUO  parecoxib vs. BUO  vehicle. £ P  0.05 SHAM
 vehicle on day 4 vs. SHAM  vehicle on days 1, 0, 1, 2, and 3.
Fig. 7. IM osmolality in parecoxib-treated and untreated BUO and SHAM rats
in protocols 2 and 3. Values are means  SE (n  6). *P  0.05 BUO vs.
SHAM. # P  0.05 water-deprived rats vs. normohydrated rats.
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was significantly lower than urine osmolality in all samples
and was lower in BUO than in SHAM rats (see Fig. 6).
Administration of parecoxib before, during, and after re-
lease of obstruction did not change interstitial osmolality
(see Fig. 6).
Effect of COX-2 inhibition on urinary prostanoid excretion
after release of obstruction. To validate inhibition of COX-2 in
the kidney, we examined the effect of parecoxib on urinary
excretion of PGE2 and the PGI2 metabolite 6-keto-PGF1 in
protocol 2. Urinary excretion of the two prostanoids increased
significantly 1 and 3 days after release of BUO compared with
SHAM rats (Fig. 5). The increase in urinary PGE2 (Fig. 5A)
and 6-keto-PGF1 excretion (Fig. 5B) was abolished by pare-
coxib 1 day after release of BUO. At 3 days after release of
obstruction, COX-2 inhibition significantly lowered urinary
excretion of the PGI2 metabolite 6-keto-PGF1.
Effect of COX-2 inhibition and water deprivation on BUO-
mediated changes in renal function after release of obstruc-
tion. To test whether urine-concentrating capacity was lowered
by COX-2 activity 3 days after release of BUO, rats were
challenged by 24 h of water deprivation in protocol 3 (Fig. 1).
Vehicle-treated SHAM rats and parecoxib-treated and un-
treated BUO rats were subjected to water deprivation. At 1–3
Fig. 8. Na-K-2Cl type 2 cotransporter (NKCC2)
mRNA and protein expression in the outer medulla
(OM) of SHAM and BUO parecoxib-treated and
untreated rats. A: representative QPCR for NKCC2
and TBP. For QPCR, 100 ng of cDNA were used.
NKCC2 mRNA was downregulated in BUO rats
compared with SHAM rats. Parecoxib did not atten-
uate the reduced NKCC2 mRNA in BUO rats.
Values are means  SE. *P  0.05 BUO vs.
SHAM. B: immunoblot reacted with anti-NKCC2
antibody. Note band at 
161 kDa. Densitometric
analyses revealed marked decrease in NKCC2 ex-
pression in the OM of BUO rats compared with
SHAM rats. Parecoxib did not prevent this de-
crease in NKCC2 expression in BUO rats. Val-
ues are means  SE. *P  0.05 BUO vs. SHAM.
C–E: immunohistochemistry for NKCC2 in kidney
medulla of SHAM, untreated BUO, and parecoxib-
treated BUO rats. Immunoperoxidase microscopy
demonstrated association of NKCC2 labeling with
apical membrane of the thick ascending limb of
Henle’s loop (TAL) in the OM of SHAM rats (C).
NKCC2 labeling was reduced in BUO rats (D).
Parecoxib did not change labeling intensity of
NKCC2 in BUO rats (E).
Table 4. Summary of densitometry of immunoblots
of Na-K-ATPase: protocol 2
SHAM  Vehicle
(n  6)
BUO  Vehicle
(n  6)
BUO  Parecoxib
(n  6)
Outer medulla 4.50.3 3.70.4 4.40.5
Inner medulla 5.51.1 1.50.4* 3.41.0
Values are means  SE. *P  0.05 BUO vs. SHAM.
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days after release of BUO before water deprivation, GFR,
plasma osmolality, diuresis, and urine osmolality changed, as
observed in protocol 2 (Table 3, Fig. 6). Similar to the results
of protocol 2, COX-2 inhibition decreased urine output signif-
icantly 1 day after release of obstruction but had no effect 2 and
3 days after BUO. However, urine output was higher after
release of BUO than in SHAM rats, consistent with impaired
urine-concentrating capacity in the BUO rats (Fig. 6A). In the
BUO rats, COX-2 inhibition by parecoxib did not significantly
change urine output and urine osmolality after water depriva-
tion (Fig. 6). However, 24 h of water deprivation led to an
increase in urine osmolality in the SHAM rats compared with
urinary osmolality at day 3 (Fig. 6B).
In vehicle-infused SHAM rats, IM tissue osmolality in-
creased significantly during water deprivation compared
with normal hydration (Fig. 7). IM tissue osmolality also
increased in the water-deprived BUO rats compared with the
normally hydrated BUO rats but was significantly lower
than in the water-deprived SHAM rats (Fig. 7). COX-2
inhibition did not increase IM tissue osmolality compared
with vehicle-infused water-deprived BUO rats (Fig. 7). Thus
urine-concentrating capacity was impaired 3 days after re-
lease of BUO and was not improved by parecoxib treatment.
IM interstitial osmolality was lower than urine osmolality in
all tested samples (Figs. 6 and 7).
Effect of COX-2 inhibition on changes in NaCl transporters
and AQPs after release of BUO. We determined the abundance
of NaCl transporters with a key role in TAL function and
urine-concentrating ability, NKCC2 and Na-K-ATPase.
NKCC2 mRNA normalized for TBP in the outer medulla
(OM) was significantly downregulated in the BUO rats com-
pared with the SHAM rats (Fig. 8A). Immunoblotting of renal
OM membrane fractions of BUO and SHAM rats revealed
marked suppression of NKCC2 abundance 3 days after release
of BUO (Fig. 8B). This downregulation at the mRNA and the
protein level was resistant to COX-2 inhibition (Fig. 8, A and B).
Immunohistochemistry revealed that labeling of NKCC2 was
localized to the apical plasma membrane of the TAL cells in
the OM (Fig. 8C). In the obstructed kidney, NKCC2 labeling
was significantly weaker (Fig. 8D). Consistent with immuno-
blotting and QPCR, there was no apparent difference in the
labeling density of NKCC2 between the parecoxib-treated and
untreated BUO rats (Fig. 8E).
The abundance of Na-K-ATPase appeared more robust and
did not change in the OM after release of BUO (Table 4), but
Na-K-ATPase abundance decreased in the IM (Table 4).
AQP2 and AQP3 protein abundance was reduced signifi-
cantly 3 days after release of BUO compared with SHAM rats
(P  0.01; Figs. 9A and 10A). Parecoxib significantly attenu-
ated the BUO-induced reduction in AQP2 and AQP3 expres-
Fig. 9. Semiquantitative immunoblot of aquaporin
(AQP)-2 in protein isolated from the IM of SHAM, BUO,
and parecoxib-treated BUO rats. A: immunoblot reacted
with affinity-purified anti-AQP2 antibody. Note 29- and
35- to 50-kDa bands representing nonglycosylated and
glycosylated forms of AQP2. Densitometric analyses re-
vealed marked decrease in AQP2 expression in the IM of
BUO rats compared with SHAM rats. Parecoxib partly
prevented this decrease in AQP2 expression in BUO
rats. *P  0.05 BUO vs. SHAM. $ P  0.05 BUO 
parecoxib vs. BUO  vehicle. B–G: immunohistochem-
istry for AQP2 in the IM of SHAM, untreated BUO, and
parecoxib-treated BUO rats. Immunoperoxidase micros-
copy demonstrated association of AQP2 labeling with
apical plasma membrane of principal cells in collecting
ducts in the IM of SHAM rats (B and E). Labeling of
AQP2 was reduced in untreated BUO rats (C and F).
Labeling in parecoxib-treated BUO rats was almost com-
parable to that in SHAM rats (D and G).
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sion 3 days after release of obstruction (P 0.05; Figs. 9A and
10A). In kidneys from SHAM rats, immunoperoxidase micros-
copy demonstrated AQP2 labeling in the apical domains of the
IM collecting duct principal cells (Fig. 9, B and E). In kidneys
from BUO rats, AQP2 labeling was less marked (Fig. 9, C and
F) than in SHAM rats. In the obstructed kidneys of parecoxib-
treated BUO rats, AQP2 labeling was identical to that in
SHAM rats (Fig. 9, D and G). AQP3 immunoreactivity was
associated with the basolateral plasma membrane of the col-
lecting duct principal cells in the IM of the obstructed kidneys
(Fig. 10, C and F), and, similar to AQP2, the labeling was less
marked 3 days after release of obstruction than in SHAM rats
(Fig. 10, B and E). AQP3 labeling of the basolateral plasma
membrane in the parecoxib-treated rats (Fig. 10, D and G) was
comparable to that in the SHAM rats (Fig. 10, B and E).
Semiquantitative immunoblotting of pAQP2 was performed
using an antibody that selectively recognizes pAQP2, which is
phosphorylated at a consensus phosphorylation site for PKA in
its COOH terminus (Ser256) (4). The abundance of pAQP2 in
the IM was significantly reduced 3 days after release of BUO
compared with SHAM rats (P  0.01; Fig. 11A) In contrast to
AQP2 and AQP3, parecoxib did not change pAQP2 abun-
dance in BUO rats compared with vehicle-infused BUO rats
(Fig. 11A). In kidney sections from SHAM rats, labeling of
pAQP2 was localized to the apical plasma membrane domains
of the collecting duct principal cells in the IM (Fig. 11, B and
E). In the obstructed kidney, pAQP2 labeling was significantly
weaker and less widely distributed than in SHAM rats (Fig. 11,
C and F). Consistent with findings from immunoblotting, there
was no apparent difference in the labeling density of pAQP2
between the parecoxib-treated and untreated BUO rats (Fig. 11,
D and G).
DISCUSSION
The main results of the present study are that COX isoforms
change inversely in the prolonged polyuric phase 3 days after
release of 24 h of BUO: medullary COX-2 mRNA, protein,
tissue distribution, and activity increase in the prolonged poly-
uric phase, whereas COX-1 mRNA and protein expression
decreases. At 3 days after BUO release, a COX-2 inhibitor
significantly lowered prostanoid excretion, while polyuria, IM
Fig. 10. Semiquantitative immunoblot of AQP3 in
protein isolated from the IM of SHAM, untreated
BUO, and parecoxib-treated BUO rats. A: immuno-
blot reacted with affinity-purified anti-AQP3 anti-
body. Note 27- and 33- to 40-kDa bands, represent-
ing nonglycosylated and glycosylated forms of
AQP3. Densitometric analyses revealed marked de-
crease in AQP3 expression in the IM in untreated
BUO rats compared with SHAM rats. Parecoxib
partly prevented this decrease in AQP3 expression
in BUO rats. *P 0.05 BUO vs. SHAM. $ P 0.05
BUO  parecoxib vs. BUO  vehicle. B–G: immu-
nohistochemistry for AQP3 in the IM of SHAM,
untreated BUO, and parecoxib-treated BUO rats.
Immunoperoxidase microscopy demonstrated asso-
ciation of AQP3 labeling with basolateral mem-
branes of principal cells in collecting ducts in the IM
of SHAM rats (B and E). Labeling of AQP3 was
reduced in untreated BUO rats (C and F). Labeling
in parecoxib-treated BUO rats was comparable to
that in SHAM rats (D and G).
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tissue osmolality, and urine-concentrating capacity were the
same as in vehicle-treated rats. Furthermore, COX-2 inhibition
partially attenuated the reduced expression of AQP2 and AQP3
in medullary collecting ducts. However, the level of NKCC2
mRNA and protein, as well as Na-K-ATPase, in the medullary
TAL (mTAL) was unchanged 3 days after release of BUO.
Thus COX-2-independent processes are responsible for the
increased urine output after release of obstruction. Collapse of
the medullary interstitial tissue osmotic gradient appears to be
a major factor in the decrease in urine-concentrating capacity.
Inverse regulation of kidney COX-1 and COX-2 after release
of obstruction. Previous data show that PGE2, TxA2, and
prostacyclin synthesis and excretion are increased in UUO and
BUO (19). Our present data support the view that COX-2 is
responsible for the increase in urinary excretion of PGE2 and
the PGI2 metabolite 6-keto-PGF1 after release of obstruction.
Immunohistochemical staining demonstrated that COX-2 was
selectively associated with the medullary interstitial cells 3
days after release of BUO. This pattern of regulation is con-
sistent with the results we and others have demonstrated in
previous studies (14, 15, 28, 36). It is well documented that
COX-2 expression can be induced by elevated extracellular
osmolality in vitro and by water deprivation or AVP infusion
in vivo (26). The present study documents a decreased inter-
stitial medullary osmolality in rats 3 days after release of BUO.
Thus it is unlikely that the BUO-induced increase in medullary
COX-2 expression was directly mediated by changes in tissue
osmolality. The present study does not address the mechanisms
involved in the medullary induction of COX-2, but several
possibilities exist. COX-2 expression is highly regulated by
inflammatory mediators. Previous studies have shown that
obstruction leads to an intense infiltration of inflammatory cells
in the renal interstitium (31).
We observed a significant decrease in COX-1 in kidney IM
3 days after release of obstruction. After 24 h of BUO without
release, COX-1 abundance was not affected (28). This differ-
ence in responsiveness of COX-1 most likely reflects a turn-
over rate of expression in the renal medulla that is much slower
for COX-1 than for COX-2. Alternatively, factors primarily
related to the release phase are responsible for this effect. It has
previously been demonstrated that COX-1 expression in the IM
was downregulated by chronic lithium treatment (23) and by
furosemide administration or water loading in rats (1). Char-
acteristically, these conditions are associated with reduced
Fig. 11. Semiquantitative immunoblot of phosphory-
lated AQP2 (pAQP2) in protein isolated from the IM of
SHAM, untreated BUO, and parecoxib-treated BUO rats.
A: immunoblot reacted with affinity-purified anti-pAQP2
antibody. Note 29- and 35- to 50-kDa bands, representing
nonglycosylated and glycosylated forms of pAQP2. Den-
sitometric analyses revealed marked decrease in pAQP2
expression in the IM of BUO rats compared with SHAM
rats. Parecoxib did not affect decreased pAQP2 ex-
pression in BUO rats. *P  0.05 BUO vs. SHAM.
B–G: immunohistochemistry for pAQP2 in the IM of
SHAM, untreated BUO, and parecoxib-treated BUO rats.
Immunoperoxidase microscopy demonstrates association
of pAQP2 labeling with apical plasma membrane of
principal cells in collecting ducts in the IM in SHAM rats
(B and E). Labeling of pAQP2 was reduced in untreated
BUO rats (C and F). Labeling in parecoxib-treated rats
was similar to that in nontreated BUO rats (D and G).
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renal interstitial osmolality. In cultured IM collecting duct
cells, COX-1 mRNA abundance is decreased by exposure of
the cells to lower ambient osmolality (1). Collectively, the data
are compatible with the notion that the change in interstitial
osmolality after release of BUO is a likely signal for the
observed decrease in COX-1 expression in kidney IM.
COX-2 inhibition does not prevent polyuria after release of
obstruction. Release of BUO is associated with a profound
postobstructive polyuria (17, 24), characterized by specific
molecular changes of transporters and channels responsible for
sodium and water transport in the renal tubules and collecting
ducts (12, 22, 24, 25). Previous studies have demonstrated that
ureteral obstruction reduces the amounts of luminal Na-K-2Cl
cotransporter and basolateral Na-K-ATPase in the mTAL of
obstructed kidney and that these reductions contribute to the
salt wasting observed after release of obstruction (20). It is well
accepted that GFR and renal blood flow are consistently
reduced (11, 16, 24), which further supports a tubular origin of
the polyuria and renal sodium loss after release of urinary tract
obstruction. To examine whether this impairment in urine-
concentrating capacity after release of obstruction is regulated
by COX-2, we examined the effects of a COX-2 inhibitor
during the first 3 days after release of obstruction. Similar to
the study of Cheng et al. (2), we observed that COX-2 inhibi-
tion significantly reduced urine output only in the acute
phase (first 24 h) after release of obstruction. These effects
could be mediated by changes in GFR, interstitial or pelvic
pressure (29), or transport proteins (28). However, 3 days
after release of obstruction, COX-2 inhibition did not alter the
profound reduction in renal function. Recently, we demon-
strated that selective COX-2 inhibition of rats subjected to 24 h
of BUO prevented downregulation of AQP2 and NKCC2 (28).
The results of the present study demonstrate that COX-2
inhibition partially prevented downregulation of AQP2 and
AQP3. However, the expression of NKCC2 mRNA and pro-
tein, as well as Na-K-ATPase, in the mTAL was unchanged 3
days after release of obstruction. A central issue in this appar-
ent controversy is the importance of a potential decrease in
collecting duct water permeability relative to the apparent
collapse of the interstitial osmotic gradient after 3 days of
release. Measurements of interstitial osmolality are technically
difficult and depend on the quantitative extraction of osmolytes
from the dried tissue and the derivation of tissue blocks from
the same level along the cortical-papillary axis. We used a
recognized published protocol (33), and the measurements
were reproducible. In no case did we observe equilibration
between tissue and urine osmolality, and urine osmolality was
always much higher than tissue osmolality. These findings are
consistent with previous reports and indicate that extraction of
osmolytes was not quantitative (28). Nevertheless, interstitial
osmolality was always significantly lower in BUO rats. Thus,
on the basis of the data, we cannot exclude the possibility that
osmotic equilibrium between urine and interstitium is reached
when BUO rats are deprived of water and that the major reason
for the markedly reduced urine-concentrating capacity is a
reduction of interstitial osmolality. The reduced interstitial
osmotic gradient in the BUO rats is readily explained by the
marked decrease in NKCC2 abundance. This interpretation is
also supported by the present results and a previous observa-
tion of no improvement in the urine-concentrating capacity,
despite a partial prevention in the reduction of AQP2 and
AQP3 abundance by parecoxib (24, 25, 28).
PKA activation and phosphorylation of AQP2 are necessary
for trafficking of the protein to the apical membrane in the
principal cells (5, 13). PGE2 stimulates removal of AQP2 from
the surface of the principal cells when it is added after vaso-
pressin treatment but does not alter the phosphorylated state of
AQP2 (38). The present finding that COX-2 inhibition prevents
downregulation of AQP2, but not pAQP2, in response to
release of obstruction suggests that inhibition of PGE2 or other
PGs leads to a reduction in AQP2 endocytosis and, therefore,
increases the abundance of AQP2 in the plasma membrane.
However, the total amount of pAQP2 was not increased by
COX-2 inhibition, suggesting that sustained phosphorylation
may not be required for maintenance of AQP2 in the apical
membrane but, rather, that phosphorylation is necessary for
translocation of AQP2 from intercellular storage vesicles to the
apical membrane, as demonstrated previously (4, 38).
In summary, the present study shows that COX-2 expression
is induced in the renal IM, whereas COX-1 expression is
reduced, 3 days after release of obstruction. Release of BUO is
associated with significant suppression of renal AQPs and renal
sodium transporters. Selective COX-2 inhibition partly pre-
vents downregulation of renal IM AQP2 and AQP3 expression
but does not affect the medullary protein level of pAQP2 and
NKCC2. COX-2 inhibition did not improve urine-concentrat-
ing capacity. Thus the present data suggest that changes in bulk
AQP2 and AQP3 proteins are less relevant for the diuresis and
impaired urine-concentrating mechanism after BUO and that
the COX-2-independent, attenuated medullary interstitial os-
motic gradient is of major significance in the prolonged poly-
uric phase of release of BUO.
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